Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.

One of the biggest growth narratives in the pharmaceutical industry right now is about weight loss medications. Glucagon-like peptide-1 (GLP-1) agonists such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are becoming ever more popular among diabetes and obesity care patients.All of these medications are made by just two companies: Novo Nordisk and Eli Lilly (NYSE: LLY). For now, Novo Nordisk is the 800-pound gorilla in the GLP-1 arena. But Lilly has made significant strides over the last couple of years, and I think its momentum is about to be supercharged.Let's dig into Lilly's latest move concerning Zepbound, its blockbuster drug for chronic weight management, and assess why now could be a lucrative time to scoop up some shares.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool